K2M Group Holdings Inc  

(Public, NASDAQ:KTWO)   Watch this stock  
Find more results for K2M, Inc
24.85
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 12.31 - 25.92
Open     -
Vol / Avg. 0.00/129,353.00
Mkt cap 985.43M
P/E     -
Div/yield     -
EPS -1.42
Shares 39.66M
Beta     -
Inst. own 51%
Aug 4, 2015
Q2 2015 K2M Group Holdings Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 16, 2015
K2M Group Holdings Inc Annual Shareholders Meeting - 8:00AM EDT - Add to calendar
May 18, 2015
K2M Group Holdings Inc at UBS Global Healthcare Conference
May 6, 2015
Q1 2015 K2M Group Holdings Inc Earnings Call
May 6, 2015
Q1 2015 K2M Group Holdings Inc Earnings Release
Mar 24, 2015
K2M Group Holdings Inc at Canaccord Genuity Musculoskeletal Conference
Mar 18, 2015
Q4 2014 K2M Group Holdings Inc Earnings Call - Webcast
Mar 18, 2015
Q4 2014 K2M Group Holdings Inc Earnings Release
Mar 11, 2015
K2M Group Holdings Inc at Barclays Healthcare Conference - Webcast
Mar 4, 2015
K2M Group Holdings Inc at Cowen Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -28.33% -31.95%
Operating margin -19.92% -25.70%
EBITD margin - -7.85%
Return on average assets -18.14% -19.89%
Return on average equity -21.10% -29.92%
Employees 448 -
CDP Score - -

Address

751 Miller Dr SE
LEESBURG, VA 20175-8993
United States - Map
+1-703-7773155 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

K2M Group Holdings, Inc. (K2M) is a global medical device company focused on designing, developing and commercializing spine technologies and techniques. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. Its products consist of implants, disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. In addition, the Company invests in the design, development and commercialization of solutions for clinical needs in the spine and minimally invasive spine (MIS) markets. The Company markets and sells its products in the United States and 28 other countries. The Company’s products are used for Complex Spine, MIS and Degenerative Spine. The Company’s technologies include MESA, Rail 4D, Deformity Cricket, SERENGETI, RAVINE, EVEREST and tifix.

Officers and directors

Daniel A. Pelak Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Eric D. Major President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Gregory S. Cole CPA Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Kostuik P. John Chief Medical Officer, Director
Age: 77
Bio & Compensation  - Reuters
Brett P. Brodnax Director
Age: 50
Bio & Compensation  - Reuters
Carlos A. Ferrer Director
Age: 57
Bio & Compensation  - Reuters
Paul B. Queally Director
Age: 50
Bio & Compensation  - Reuters
Sean M. Traynor Director
Age: 45
Bio & Compensation  - Reuters
Michael Turpin Director
Age: 53
Bio & Compensation  - Reuters